Cyclerion Therapeutics (NASDAQ:KRSA) Research Coverage Started at Wedbush

Wedbush began coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a report issued on Monday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $44.00 price objective on the stock.

Other research analysts have also recently issued reports about the company. UBS Group started coverage on Cyclerion Therapeutics in a report on Friday, September 11th. They issued a “buy” rating and a $55.00 price target on the stock. Wall Street Zen raised shares of Cyclerion Therapeutics to a “sell” rating in a report on Saturday, October 3rd. Stifel Nicolaus began coverage on shares of Cyclerion Therapeutics in a research report on Monday, September 14th. They set a “buy” rating and a $43.00 price objective on the stock. TD Cowen started coverage on shares of Cyclerion Therapeutics in a report on Monday, September 14th. They issued a “buy” rating on the stock. Finally, Guggenheim started coverage on shares of Cyclerion Therapeutics in a research report on Monday, September 28th. They set a “buy” rating and a $70.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Cyclerion Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $53.00.

Cyclerion Therapeutics Price Performance

NASDAQ KRSA opened at $31.65 on Monday. The stock has a market capitalization of $21.21 million, a PE ratio of -2.72 and a beta of 1.72. Cyclerion Therapeutics has a twelve month low of $7.19 and a twelve month high of $59.36.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases involving the central nervous system, cardiovascular system, kidneys and other organs. The company’s research centered on soluble guanylate cyclase stimulators, a class of compounds designed to influence cellular signaling pathways associated with blood flow, inflammation and tissue function.

Cyclerion’s development portfolio historically included IW-6463, an investigational central nervous system therapy, as well as olinciguat and praliciguat, which were studied for potential applications in conditions including neurodegenerative disease, sickle cell disease and diabetic kidney disease.